More cell and gene therapies are coming, raising unique challenges for drug developers and regulators. In this conversation with Dr. Peter Marks, director of FDA’s CBER, we will discuss how the FDA is adapting to new cell and gene therapy technologies, the development of new regulatory tools, and the careful balance between benefit and risk. |
